Cardiac myosin activation: a potential therapeutic approach for systolic heart failure.
Cardiac myosin activation: a potential therapeutic approach for systolic heart failure.
复制标题
DOI:
10.1126/science.1200113
复制
发表时间:
2011-03-18
期刊:
影响因子:
--
通讯作者:
Morgans DJ
中科院分区:
文献类型:
--
作者:
Malik FI;Hartman JJ;Elias KA;Morgan BP;Rodriguez H;Brejc K;Anderson RL;Sueoka SH;Lee KH;Finer JT;Sakowicz R;Baliga R;Cox DR;Garard M;Godinez G;Kawas R;Kraynack E;Lenzi D;Lu PP;Muci A;Niu C;Qian X;Pierce DW;Pokrovskii M;Suehiro I;Sylvester S;Tochimoto T;Valdez C;Wang W;Katori T;Kass DA;Shen YT;Vatner SF;Morgans DJ
Decreased cardiac contractility is a central feature of systolic heart failure. Existing drugs increase cardiac contractility indirectly through signaling cascades but are limited by their mechanism-related adverse effects. To avoid these limitations, we previously developed omecamtiv mecarbil, a small-molecule, direct activator of cardiac myosin. Here, we show it binds to the myosin catalytic domain and operates by an allosteric mechanism to increase the transition rate of myosin into the strongly actin-bound force-generating state. Paradoxically, it inhibits adenosine 5′-triphosphate (ATP) turnover in the absence of actin, which suggests that it stabilizes an actin-bound conformation of myosin. In animal models, omecamtiv mecarbil increases cardiac function by increasing the duration of ejection without changing the rates of contraction. Cardiac myosin activation may provide a new therapeutic approach for systolic heart failure.
登录
查看更多内容
影响因子:
2.9
作者:
LYMN, RW;TAYLOR, EW
通讯作者:
TAYLOR, EW
影响因子:
56.9
作者:
Grimsby, J;Sarabu, R;Grippo, JF
通讯作者:
Grippo, JF
影响因子:
15.9
作者:
KOMAMURA, K;SHANNON, RP;VATNER, SF
通讯作者:
VATNER, SF
DOI:
10.1152/ajpheart.1999.277.1.h388
发表时间:
1999-07-01
影响因子:
4.8
作者:
Shen, YT;Lynch, JJ;Wiedmann, RT
通讯作者:
Wiedmann, RT
影响因子:
5.5
作者:
CLEEMANN, L;MORAD, M
通讯作者:
MORAD, M